InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,340.24
(
0.39%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: None

Wednesday, 11/28/2012 10:52:10 PM

Wednesday, November 28, 2012 10:52:10 PM

Post# of 80490
Can someone explain benefit of orphan drug status?

I mean if dasatinib, nilotinib, bosutinib, and very soon ponatinib all have orphan drug status in US and EU for CML then what is the benefit? Can there really be 7 years of market exclusivity in US and 10 years in EU for four relatively new drugs for the same indication?

Or is orphan drug status just a tax benefit?


Thanks.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up